Enterprise Value

530.8M

Cash

244M

Avg Qtr Burn

-18.72M

Short % of Float

17.87%

Insider Ownership

2.18%

Institutional Own.

85.85%

Qtr Updated

02/29/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NX-1607 Details
Cancer, Solid tumor/s

Phase 1

Data readout

NX-5948 Details
Cancer, B-cell malignancies

Phase 1

Data readout

NX-2127 (BTK degrader) Details
Chronic lymphocytic leukemia, Blood cancer, Cancer, B-cell malignancies, Non-Hodgkin lymphoma, Diffuse large B cell lymphoma, Mantle cell lymphoma

Phase 1

Update

NX-1607 + paclitaxel Details
Solid tumor/s, Cancer

Phase 1a

Data readout

DeTIL-0255 Details
Ovarian cancer, Cancer, Cervical cancer, Endometrial cancer

Failed

Discontinued